Please assess the completion status of the following clinical trial:

Trial Title: Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject provides written informed consent and HIPAA authorization before any study procedures are conducted~2. Subject is female~3. Subject is aged 21-80 years~4. Subject has a body mass index (BMI) \< 37 kg/m2~5. Subject is menopausal either naturally (at least 12 months amenorrheic) or 6 weeks after a bilateral salpingo-oophorectomy prior to natural menopause subjects with hysterectomy only must have a serum Follicle Stimulating Hormone \> 40 milli-International unit /mL~6. Subject has vulvovaginal atrophy with dyspareunia~7. Subject has had a normal mammogram within the last 6 months~8. Subject has normal pap smear within last 6 months~9. Subject has an endometrial stripe ≤ 4 mm within the last 6 months if she has a uterus~10. Subject agrees to comply with the study procedures and visits.~Exclusion Criteria:~1. Subject has a hypersensitivity to any of the ingredients of ospemifene~2. Subject has used ospemifene in the past~3. Subject has documented or suspected breast cancer, history of heart attack or stroke~4. Subject has clinically significant findings on physical examination~5. Subject has uncontrolled hypertension~6. Subject has any chronic medical condition or psychologic disorder that the Principal Investigator feels makes her ineligible for the study~7. Subject is currently on local or systemic androgen therapy including local or systemic testosterone (washout 14 days for local or topical androgen or non-depot injection, 1 month for depot, 6 months for pellet~8. Subject is currently on local or systemic estrogen therapy or androgen therapy (washout 14 days for vaginal estrogen, 60 days for oral/transdermal therapy)~9. Subject is currently using a Selective Estrogen Receptor Modulator (SERM) or products that have estrogenic or anti-estrogenic effects within last month~10. Subject currently using itraconazole, ketoconazole, digitalis or alkaloids heparin or strong cytochrome P 450 3A4 inhibitors~11. Subject has a history of substance abuse within 12 months prior, or consuming \> 14 alcoholic drinks per week~12. Subject has received an investigational drug within 30 days prior to signing consent~13. Subject has any condition or exhibits behavior that indicates to the Principal Investigator that the Subject is unlikely to be compliant with study procedures and visits.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ospemifene open label (Type: EXPERIMENTAL): 60 mg ospemifene daily for 20 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).